<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287272</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AA1-12</org_study_id>
    <secondary_id>2013-005491-18</secondary_id>
    <nct_id>NCT02287272</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of CHF5993 With Cimetidine</brief_title>
  <official_title>Open-label, Randomized, Single Dose, 2-sequence, 2-period Cross-over Study to Investigate the Effect of Inhibition of the Organic Cation Transport in the Kidneys by Cimetidine on the Pharmacokinetics of the CHF5993 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic interaction when CHF5993&#xD;
      (pressurized metered-dose inhaler (pMDI) is administered with Cimetidine (probe inhibitor of&#xD;
      the organic cation transport in the kidneys), by comparing the systemic exposure (AUC0-t) of&#xD;
      Glycopyrronium Bromide (GB), after a single dose of the fixed combination CHF 5993 pMDI&#xD;
      administered alone or at steady-state of Cimetidine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the safety and tolerability of study treatments based on evaluation of vital signs,&#xD;
      electrocardiograms and clinical laboratory assessments will be also evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) of Glycopyrronium Bromide</measure>
    <time_frame>pre-dose, 5, 10,15,30min, 1,2,4,6,8,12hr post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetic parameters for Glycopyrronium Bromide</measure>
    <time_frame>pre-dose-72hr post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of Glycopyrronium Bromide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetic parameters for Formoterol</measure>
    <time_frame>pre-dose-24hr post dose</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUC0-t), 0 to 24 hours (AUC0-24), 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of Formoterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetic parameters for B17MP</measure>
    <time_frame>pre-dose- 72hr post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUC0-t), 0 to 24 hours (AUC0-24), 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of B17MP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Treatment period R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment period T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cimetidine plus CHF5993 pMDI: repeated doses of oral cimetidine for 6 days plus a single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 pMDI</intervention_name>
    <description>4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB</description>
    <arm_group_label>Treatment period R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimetidine plus CHF5993 pMDI</intervention_name>
    <description>Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)</description>
    <arm_group_label>Treatment period T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's written informed consent obtained prior to any study-related procedure;&#xD;
&#xD;
          2. Male and female healthy volunteers aged 18-45 years inclusive;&#xD;
&#xD;
          3. Male subjects with female partner of childbearing potential: they or their partner&#xD;
             must be willing to use (at least) one or more reliable methods of contraception (see&#xD;
             exclusion criterion n.1 for details*) from the time of dose administration and until&#xD;
             the end of the study. Male subjects must not donate sperm for 90 days after the last&#xD;
             dose of study drug. Male subjects with partners of non-childbearing potential are not&#xD;
             required to use contraception;&#xD;
&#xD;
          4. Able to understand the study procedures, the risks involved and ability to be trained&#xD;
             to correctly use the devices;&#xD;
&#xD;
          5. Body Mass Index (BMI) between 18.0 and 30.0 kg/m2 inclusive;&#xD;
&#xD;
          6. A serum creatinine within the normal range (0,7-1,2 mg/dL) and an eGFR &gt;80 mL/min/1.73&#xD;
             m2;&#xD;
&#xD;
          7. Non- or ex-smokers who smoked &lt; 5 pack years (pack-years = the number of cigarette&#xD;
             packs per day times the number of years) and stopped smoking &gt; 1 year;&#xD;
&#xD;
          8. Good physical and mental status, determined on the basis of the medical history and a&#xD;
             general clinical examination;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects: pregnant or lactating women and all women physiologically capable of&#xD;
             becoming pregnant (i.e. women of childbearing potential) UNLESS they meet the&#xD;
             following definition of post-menopausal: 12 months of natural (spontaneous) documented&#xD;
             amenorrhea or are willing to use one or more of the following reliable *methods of&#xD;
             contraception:&#xD;
&#xD;
               1. surgical sterilization (e.g. bilateral tubal ligation, hysterectomy for females;&#xD;
                  vasectomy for males)&#xD;
&#xD;
               2. hormonal contraception (implantable, patch, oral), intrauterine device (IUD) or&#xD;
                  intrauterine system (IUS)&#xD;
&#xD;
               3. barrier methods (male or female condom, diaphragm, sponge, cervical cap).&#xD;
&#xD;
          2. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before&#xD;
             inhalation of the study medication;&#xD;
&#xD;
          3. Positive HIV1 or HIV2 serology;&#xD;
&#xD;
          4. Positive results from the Hepatitis serology which indicates acute or chronic&#xD;
             Hepatitis B or Hepatitis C;&#xD;
&#xD;
          5. History of substance abuse or drug abuse within 12 months prior to screening visit or&#xD;
             with a positive urine drug screen at screening;&#xD;
&#xD;
          6. An abnormal triplicate 12-lead ECG (QRS&gt; 120 msec, PR&gt; 220 msec, HR &lt; 40 bpm, HR &gt; 110&#xD;
             bpm) at screening or at randomization;&#xD;
&#xD;
          7. Subjects whose electrocardiogram (12-lead ECG) shows QTcF &gt;450 ms for males and &gt;470&#xD;
             for females at screening or at randomization;&#xD;
&#xD;
          8. Subjects whose DBP is higher than 90 mmHg or SBP is higher than 140 mmHg at screening&#xD;
             or at randomization;&#xD;
&#xD;
          9. Subjects who received any investigational new drug, or participated in clinical study&#xD;
             within the last 8 weeks before screening;&#xD;
&#xD;
         10. History of hypersensitivity to M3 Antagonists, Î²2-agonist, corticosteroids or any of&#xD;
             the excipients contained in any of the formulations used in the trial;&#xD;
&#xD;
         11. Treatment within the previous 3 months before the screening visit until the end of the&#xD;
             study procedures in the last treatment period with any drug known to have a&#xD;
             well-defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole);&#xD;
&#xD;
         12. Subjects who refuse to abstain from alcohol or xanthine containing foods or beverages&#xD;
             or grapefruit containing foods or beverages from 48 hour prior to each intake of study&#xD;
             medication until the end of confinement at the clinical centre;&#xD;
&#xD;
         13. Heavy caffeine drinker (&gt; 5 cups or glasses of caffeinated beverages e.g., coffee,&#xD;
             tea, cola per day);&#xD;
&#xD;
         14. Subjects who have a positive urine test for cotinine at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wouter Haazen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Life Science Services SGS Belgium NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Life Science Services SGS Belgium NV</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.chiesi.com/clinic/CSR_Synopsis_CCD-05993AA1-12.pdf</url>
    <description>CSR Synopsis available in the Chiesi Clinical Study Register</description>
  </link>
  <results_reference>
    <citation>Mariotti F, Ciurlia G, Spaccapelo L, Muraro A, Acerbi D. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993. Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):269-279. doi: 10.1007/s13318-016-0345-2.</citation>
    <PMID>27209586</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD- cimetidine- drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

